Itepekimab Astepro anti-IL-33 asthma

Indicated For

asthma

About This Medication

# Itepekimab Patient Guide: How to Get Itepekimab at Low or No Cost **Important Notice:** As of March 2026, itepekimab (SAR440340/REGN-3500) is an investigational biologic drug developed by Sanofi and Regeneron Pharmaceuticals. It is **not yet FDA-approved** and unavailable through commercial prescription assistance programs. No patient assistance program exists because the drug is only accessible via clinical trials for conditions like chronic rhinosinusitis with nasal polyps (CRSwNP) or chronic obstructive pulmonary disease (COPD).[1][2][4][6] This guide provides general information on accessing investigational drugs and steps for trial participation, which may offer free treatment. ## About Itepekimab Itepekimab is a fully human monoclonal antibody that targets and inhibits interleukin-33 (IL-33), a protein that initiates and amplifies inflammation in respiratory diseases. It is being studied as an add-on therapy to standard treatments like intranasal corticosteroids for adults with inadequately controlled **chronic rhinosinusitis with nasal polyps (CRSwNP)** (Phase 3 CEREN1 trial, NCT06834347) or **COPD** (AERIFY trials).[1][2][3][4][5][6] - **For CRSwNP:** A 52-week Phase 3 trial evaluates two subcutaneous (SC) dosing regimens (low and high dose) vs. placebo, plus mometasone furoate nasal spray. Total study duration: up to 76 weeks (4-week screening, 52-week treatment, 20-week follow-up).[1][2][5] - **For COPD:** Recent Phase 3 trials showed mixed results—AERIFY-1 met endpoints (27% reduction in exacerbations on every-2-week dose), but AERIFY-2 did not, clouding approval prospects.[4] Itepekimab is administered via subcutaneous injection, typically every 2 weeks or monthly in trials. Common side effects in studies include injection-site reactions, but full safety data is pending.[1][4] Since it's investigational, patients cannot obtain it via pharmacy but may qualify for free access through trials. Always consult your doctor to see if you fit trial criteria (e.g., age 18+, moderate-to-severe symptoms despite standard care).[1][4] ## Who Qualifies for Access? **No commercial patient assistance program exists.** Access is limited to clinical trial participants. General eligibility for itepekimab trials includes: - Adults (18+ years) with inadequately controlled CRSwNP or COPD. - Ongoing standard therapies (e.g., inhaled corticosteroids for COPD, intranasal steroids for CRSwNP). - Specific biomarkers (e.g., elevated eosinophils in some COPD studies).[1][2][4][5] **Income Eligibility:** Clinical trials do not use income thresholds; they are free for qualified participants regardless of finances. No FPL-based limits apply, unlike commercial PAPs.[1] ## Income Eligibility Breakdown | Household Size | Annual Income Limit | % of Federal Poverty Level (FPL) | Notes | |---------------|---------------------|----------------------------------|-------| | Individual | N/A | N/A | Trials are free; no income requirements. Contact trial sites for details.[1] | | Couple | N/A | N/A | Free medication and monitoring provided.[2] | | Family of 3 | N/A | N/A | Enrollment based on medical criteria only.[4] | | Family of 4 | N/A | N/A | Sanofi/Regeneron cover all costs.[6] | ## Insurance Requirements **None for trials.** Participation is free, including drug, visits, and tests—no insurance needed. Medicare/Medicaid patients can join without coverage issues. Trials exclude those in other studies or with certain comorbidities.[1][2] ## Step-by-Step Application Process for Trials 1. **Consult Your Doctor:** Discuss if itepekimab trials suit your condition. Get referrals to sites (e.g., UChicago Medicine for NCT06834347).[2] 2. **Search Trials:** Use ClinicalTrials.gov (search 'itepekimab' or NCT06834347). Check for open sites near you.[1] 3. **Contact Coordinator:** Call/email trial sites. Provide medical history. 4. **Screening Visit:** Attend 4-week screening (1 in-person visit) for eligibility tests (e.g., endoscopy for polyps, lung function).[5] 5. **Enrollment:** If eligible, start 52-week treatment (9 site visits, 20 phone/home visits). Randomization to itepekimab or placebo.[1][5] 6. **Follow-Up:** 20-week safety monitoring post-treatment.[2] **Application Phone/URL:** Varies by site. Example: ClinicalTrials.gov listings or manufacturer trials pages (Sanofi/Regeneron).[1][6] ## Timeline and Delivery - **Processing/Screening:** 4 weeks.[5] - **Treatment:** 52 weeks, SC injections at clinic or home.[1] - **Total:** Up to 76 weeks. - **Delivery:** Administered at visits; no home shipment like commercial drugs. Reauthorization not needed—fixed trial duration.[1] ## Alternatives if Denied or No Trials Available - **Other Biologics:** For CRSwNP, FDA-approved Dupixent (dupilumab) by Sanofi/Regeneron—check their PAP (dupixent.com/support).[3] - **COPD Options:** Inhaled therapies, or emerging biologics post-approval. - **Biosimilars:** None for itepekimab (investigational).[6] - **Expanded Access:** If trials close, ask Sanofi/Regeneron about compassionate use (rare pre-approval).[4] - **Other Trials:** Search for IL-33 inhibitors or similar (e.g., bronchiectasis Phase 2).[6] ## Disclaimer This guide is for informational purposes only and not medical advice. Itepekimab is **not approved**; trial access involves risks like placebo assignment or unknown side effects. Consult healthcare providers. Program details may change—verify via ClinicalTrials.gov. No guarantees of enrollment. Sanofi/Regeneron not liable for this guide. Word count: 912.

Program information last verified: March 30, 2026